H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
H e m a t o lo g y E d u c a t io n - European Hematology Association
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
16 th Congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n<br />
for Newly Diagnosed Chronic Mye<strong>lo</strong>id Leukemia. N Engl J<br />
Med. 2010;362:2251-9.<br />
35. Hughes TP, Hochhaus A, Sagl<strong>io</strong> G et al.: ENESTnd Update:<br />
Continued Super<strong>io</strong>rity of Ni<strong>lo</strong>tinib Versus Imatinib In<br />
Patients with Newly Diagnosed Chronic Mye<strong>lo</strong>id Leukemia<br />
In Chronic Phase (CML-CP). B<strong>lo</strong>od 2010;116:Abstract 207.<br />
36. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus<br />
Imatinib in Newly Diagnosed Chronic-Phase Chronic<br />
Mye<strong>lo</strong>id Leukemia. N Engl J Med. 2010;362:2260-70.<br />
37. Shah N, Kantarjian HM, Hochhaus A, et al. Dasatinib Versus<br />
Imatinib In Patients with Newly Diagnosed Chronic Mye<strong>lo</strong>id<br />
Leukemia In Chronic Phase (CML-CP) In the DASISION<br />
Trial: 18-Month Fol<strong>lo</strong>w-up. B<strong>lo</strong>od 2010;116:Abstract 206.<br />
38. Gambacorti-Passerini C, Kim DW, Kantarjian HM, et al. An<br />
Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus<br />
Imatinib in Patients With Newly Diagnosed Chronic Phase<br />
Chronic Mye<strong>lo</strong>id Leukemia. B<strong>lo</strong>od. 2010;116:Abstract 208.<br />
39. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib<br />
induces durable cytogenetic responses in patients with chronic<br />
mye<strong>lo</strong>genous leukemia in chronic phase with resistance or<br />
intolerance to imatinib. Leukemia. 2008;22:1200-06.<br />
40. Kantarjian H, Giles F, Bhalla K, et al. Update On Imatinib-<br />
Resistant Chronic Mye<strong>lo</strong>id Leukemia Patients in Chronic<br />
Phase (CML-CP) On Ni<strong>lo</strong>tinib Therapy at 24 Months: Clinical<br />
Response, Safety, and Long-Term Outcomes B<strong>lo</strong>od.<br />
2009:114:Abstract 1129.<br />
41. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for<br />
newly diagnosed patients with chronic mye<strong>lo</strong>id leukemia:<br />
incidence of sustained responses in an intent<strong>io</strong>n-to-treat<br />
analysis. J Clin Oncol. 2008;26:3358-63.<br />
42. Lucas CM, Wang L, Austin GM, et al. A populat<strong>io</strong>n study of<br />
imatinib in chronic mye<strong>lo</strong>id leukaemia demonstrates <strong>lo</strong>wer<br />
efficacy than in clinical trials. Leukemia. 2008;22:1963-6.<br />
43. Rousse<strong>lo</strong>t P, Huguet F, Rea D, et al. Imatinib mesylate discontinuat<strong>io</strong>n<br />
in patients with chronic mye<strong>lo</strong>genous leukemia in<br />
complete molecular remiss<strong>io</strong>n for more than 2 years. B<strong>lo</strong>od.<br />
2007;109:58-60.<br />
44. Cortes J, O’Brien S, Kantarjian H. Discontinuat<strong>io</strong>n of imatinib<br />
therapy after achieving a molecular response. B<strong>lo</strong>od. 2004;<br />
104:2204-5.<br />
45. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome<br />
in two CML patients who discontinued imatinib therapy<br />
after achieving a molecular remiss<strong>io</strong>n. Leuk Res. 2004;<br />
28:71-3.<br />
46. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide<br />
vaccine associated with imatinib or interferon in<br />
patients with chronic mye<strong>lo</strong>id leukaemia and persistent residual<br />
disease: a multicentre observat<strong>io</strong>nal trial. Lancet. 2005;365:657-62.<br />
47. Qazilbash MH, Wieder E, R<strong>io</strong>s R, et al. Vaccinat<strong>io</strong>n with the<br />
PR1 Leukemia-Associated Antigen Can Induce Complete<br />
Remiss<strong>io</strong>n in Patients with Mye<strong>lo</strong>id Leukemia. B<strong>lo</strong>od.<br />
2004;104:77a (Abstract 259).<br />
48. Li Z, Qiao Y, Liu B, et al. Combinat<strong>io</strong>n of Imatinib Mesylate<br />
with Auto<strong>lo</strong>gous Leukocyte-Derived Heat Shock Protein and<br />
Chronic Mye<strong>lo</strong>genous Leukemia. Clin Cancer Res. 2005;<br />
11:4460-8.<br />
49. Smith BD, Kasamon YL, Kowalski J, et al. K562/GM-CSF<br />
immunotherapy reduces tumor burden in chronic mye<strong>lo</strong>id<br />
leukemia patients with residual disease on imatinib mesylate.<br />
Clin Cancer Res. 2010;16:338-47.<br />
50. Bocchia M, Defina M, Ippoliti M, et al. BCR-ABL Derived<br />
Peptide Vaccine in Chronic Mye<strong>lo</strong>id Leukemia Patients with<br />
Molecular Minimal Residual Disease During Imatinib:<br />
Interim Analysis of a Phase 2 Multicenter GIMEMA CML<br />
Working Party Trial B<strong>lo</strong>od. 2009;114:Abstract 648.<br />
51. Burchert A, Müller MC, Kostrewa P, et al. Sustained molecular<br />
response with interferon alfa maintenance after induct<strong>io</strong>n<br />
therapy with imatinib plus interferon alfa in patients with<br />
chronic mye<strong>lo</strong>id leukemia. J Clin Oncol. 2010;28:1429-35.<br />
52. Dierks C, Beigi R, Guo GR, et al. Expans<strong>io</strong>n of Bcr-Ablpositive<br />
leukemic stem cells is dependent on Hedgehog pathway<br />
activat<strong>io</strong>n. Cancer Cell. 2008;14:238-49.<br />
53. Quintas-Cardama A, Cortes JE, O’Brien S, et al. Dasatinib<br />
early intervent<strong>io</strong>n after cytogenetic or hemato<strong>lo</strong>gic resistance<br />
to imatinib in patients with chronic mye<strong>lo</strong>id leukemia.<br />
Cancer. 2009;115:2912-21.<br />
| 126 | Hemato<strong>lo</strong>gy Educat<strong>io</strong>n: the educat<strong>io</strong>n programme for the annual congress of the <strong>European</strong> Hemato<strong>lo</strong>gy Associat<strong>io</strong>n | 2011; 5(1)
Change language